ArticleBMC veterinary research2015
Reduced canine BRCA2 expression levels in mammary gland tumors.
Article in BMC veterinary research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Exploring the Therapeutic Potential of BRCA1 and BRCA2 as Targets in Canine Oncology: A Comprehensive Review of Their Role in Cancer Development and Treatment.International journal of molecular sciences · 2025Pooled it
- Establishment and molecular characterization of novel luminal A and luminal B canine mammary cancer cell lines for comparative oncology.Veterinary world · 2025Article
- Comparative epigenomics to clinical trials in human breast cancer and canine mammary tumor.Animal cells and systems · 2025Review
- Canine Mammary Tumors: Classification, Biomarkers, Traditional and Personalized Therapies.International journal of molecular sciences · 2024Review
- Research progress of good markers for canine mammary carcinoma.Molecular biology reports · 2023Review
- Canine Mammary Cancer: State of the Art and Future Perspectives.Animals : an open access journal from MDPI · 2023Review
- Identifying the Risk Factors for Malignant Mammary Tumors in Dogs: A Retrospective Study.Veterinary sciences · 2023Article
- Transcriptomic Profile of Canine Mammary Ductal Carcinoma.International journal of molecular sciences · 2023Article
- A Highly Conserved Region in BRCA2 Suppresses the RAD51-Interaction Activity of BRC Repeats.Veterinary sciences · 2023Article
- DNA damage response proteins in canine cancer as potential research targets in comparative oncology.Veterinary and comparative oncology · 2022Review
- CircRNA Expression Profiles in Canine Mammary Tumours.Veterinary sciences · 2022Article
- LncRNA Expression Profiles in Canine Mammary Tumors Identify lnc34977 as a Promoter of Proliferation, Migration and Invasion of Canine Mammary Tumor Cells.Veterinary sciences · 2022Article
- Liquid Biopsy as a Diagnostic and Prognostic Tool for Women and Female Dogs with Breast Cancer.Cancers · 2021Article
- Reduced translation efficiency due to novel splicing variants in 5' untranslated region and identification of novel cis-regulatory elements in canine and human BRCA2.BMC molecular and cell biology · 2021Article
- A Statistical Analysis of Risk Factors and Biological Behavior in Canine Mammary Tumors: A Multicenter Study.Animals : an open access journal from MDPI · 2020Article
- Spontaneous and Induced Animal Models for Cancer Research.Diagnostics (Basel, Switzerland) · 2020Review
- Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy.BMC veterinary research · 2020Review
- Naturally-Occurring Canine Mammary Tumors as a Translational Model for Human Breast Cancer.Frontiers in oncology · 2020Review
- Current biomarkers of canine mammary tumors.Acta veterinaria Scandinavica · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMammary tumors are the most common tumor type in intact female dogs. Recently, the breast cancer 2 early onset (BRCA2) gene was proposed to be associated with tumorigenesis in dogs. The expression level of BRCA2 is important for its DNA repair function in mammalian cells, and its expression level is linked to tumorigenesis in mammary tissue. However, the expression of canine BRCA2 in mammary tumors is unclear.
resultsBRCA2 mRNA levels were compared between seven mammary gland samples and seventeen mammary tumor samples isolated from dogs. The expression level of canine BRCA2 in mammary tumor samples was lower than levels in mammary gland samples. We attempted to identify why the BRCA2 expression level was decreased in mammary tumor samples by promoter sequencing analysis; however, we did not find any mutations in the canine BRCA2 promoter that altered BRCA2 transcription levels. We did detect two types of BRCA2 splice variants in 8 mammary tumor samples. One of the variants induced a frame-shift mutation that could lead to nonsense-mediated mRNA decay, a ubiquitous cellular mechanism that eliminates mRNA containing a premature termination codon.
conclusionsReduced expression of canine BRCA2 mRNA in mammary tumor samples is a possible mechanism to explain mammary tumor development in dogs. One possible reason for reduced BRCA2 mRNA levels in these tumor samples was nonsense-mediated mRNA decay, not mutations in the BRCA2 promoter region. While it remains unclear why canine BRCA2 expression levels are reduced in mammary tumor samples, this study found that the expression level of BRCA2 was associated with canine mammary tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.